Indian Pharma Set for Billions as Semaglutide Patent Expires in 2026

• Semaglutide's patent expires in 2026 in India, Canada, Brazil, China, and Turkey, opening doors for generic versions.
• This expiry is a game-changer for Indian pharmaceutical companies, promising billions in earnings and market growth.
• Major GLP-1 drugs like Eli Lilly's Mounjaro (₹496 crore sales in 7 months) and Novo Nordisk's Wegovy entered India in 2025.
• Generic entry could halve Semaglutide prices from ₹8,000-10,000 to ₹4,000, significantly increasing patient access.
• Analysts predict Semaglutide could contribute 4-5% to India's total pharma market and 1-2% to industry growth.

Why It Matters: Semaglutide patent expiry in 2026 offers Indian pharma a multi-billion dollar opportunity in the weight-loss drug market.